Adeleke O.A., Choonara Y.E., Du Toit L.C., Pillay V.
University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, Johannesburg, South Africa
Adeleke, O.A., University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, Johannesburg, South Africa; Choonara, Y.E., University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, Johannesburg, South Africa; Du Toit, L.C., University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, Johannesburg, South Africa; Pillay, V., University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, Johannesburg, South Africa
Carbamazepine (CBZ) is a leading molecule in the management of epilepsy. Surveys have revealed that a sufficient lack of therapeutically efficient CBZ transbuccal formulation exists. Therefore, this investigation was directed toward designing multiparticulate composite construct (MCC) for the transbuccal delivery of CBZ. The MCC was formulated using interphase, coparticulate- cosolvent homogenization technique, and lyophilization. In vitro, ex vivo, and in vivo investigations were performed. The mesoporous (pore width = 80.1233 Å) MCC was mechanically stable (Cyrillic capital letter Ukrainian ie D = 0.0290 J, MF = 8.5490 N/mm) and resilient (M R = 5.5040%). It demonstrated distinctive controlled release (9.9800%/h), permeation enhancing (10.8730%/h), drug loading (90.0541%), and bioadhesive (ωadh = 0.0034 J, Fdet = 1.0751 N) capacities. In vivo studies on pigs showed the ability of the MCC to effectively initiate and regulate transbuccal permeation of CBZ as visualized by outcomes of the quantitative and qualitative assessments of isolated plasma samples. Furthermore, comparisons of in vitro and in vivo data of MCC with a conventional product highlighted its capability to attain higher bioavailability and more controlled release trends. Histological and cytological investigations confirmed that the MCC is biocompatible. The mathematical model produced relevant pharmacokinetics and in vitro/in vivo correlation information. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
carbamazepine; placebo; adhesion; animal experiment; article; biocompatibility; cheek mucosa; composite material; controlled release formulation; controlled study; cytology; cytotoxicity assay; drug bioavailability; drug blood level; drug penetration; drug screening; drug solubility; drug stability; ex vivo study; experimental pig; female; freeze drying; histology; in vivo study; morphometrics; multiparticulate composite construct; nonhuman; particle size; physical parameters; qualitative analysis; surface property; sustained release preparation; weight; Administration, Buccal; Animals; Anticonvulsants; Biological Availability; Carbamazepine; Delayed-Action Preparations; Models, Biological; Mouth Mucosa; Porosity; Swine